Encore Dermatology has picked up a late-stage pipeline drug via a deal with India's Dr. Reddy's Laboratories.

Parexel has joined forces with the Osaka International Cancer Institute to help “drive greater efficiencies” across trials in Japan.

Former Zealand Pharma chief David Horn Solomon, M.D., has taken up the challenge of guiding biotech Akari during an increasingly tumultuous period.

Samsung is taking its first steps beyond the lower risk, lower reward world of biosimilars by teaming up with Takeda to co-develop drugs.

The Big Pharma is paying €25 million to work with Ethris on respiratory diseases and bag the option to license the fruits of the collaboration.

Blade Therapeutics is looking to sharpen its focus after hiring Bristol-Myers Squibb’s former fibrosis research lead as its new EVP of research.

The deal continues the retreat from infectious diseases Medivir began after Gilead and others cornered the hepatitis C market.

We all know that biotech M&A activity has been pretty sluggish in 2017, but new stats out from Bloomberg show just how quiet things have been.

Bryan Irving made his name in a decadelong stint at Genentech, during which he performed research that gave rise to anti-PD-L1 antibody Tecentriq.